Drug intelligence / Profile preview

SD-B04

Development stage: Preclinical
Lead developer: Sinedore Medicine
Modality: Recombinant Proteins and Enzymes

Overview

SD-B04 is a botulinum toxin-based protein therapeutic being developed by Sinedore Medicine for the treatment of hyperhidrosis (excessive sweating) and sebum control. As a botulinum toxin derivative, it is designed to inhibit the release of the neurotransmitter acetylcholine from nerve terminals by cleaving synaptosomal-associated protein 25 (SNAP-25), a key component of the SNARE protein complex required for synaptic vesicle exocytosis. In hyperhidrosis, this blockade prevents the stimulation of eccrine sweat glands. For sebum control, the toxin is intended to modulate sebaceous gland activity to reduce oil production. SD-B04 is currently in the lead optimization and preclinical stages of development.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on SD-B04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-B04.

Explore the full profile